SUPNSupernus Pharmaceuticals, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though priced for +32% a year vs +9% a year delivered.
Priced for ~32% a year FCF growth. The price demands more than its three-year revenue growth of 9% a year, priced for acceleration.
In its normal range: P/E 27.4 vs a 26.1 median over 34 quarters (+5% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SUPN's price assumes
Today's price asks for 32% free cash flow growth a year; over the last three years Supernus Pharmaceuticals, Inc. delivered −36%, the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.72%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +32%
Growth the price implies · The price pays for +32% free cash flow growth a year for a decade; the business has delivered −36% a year over the last three.
- Price / book
- 2.45
Price / book · today's price, fiscal year to Dec 31, 2025
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 2.45
- EV / EBIToperating margin −16%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 3.43
- Free cash flow, trailing twelve months
- $19M
- Market capitalisation
- $2.60B
- 3-year revenue growth
- +9.4%
- 3-year free cash flow growth
- −36%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #21 of 41 by RyuScore